NCT00909311

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Randomized, Open-label, 2-period Cross-over Study in Healthy Adults to Evaluate the Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of food on pharmacokinetics, safety and tolerability of an experimental Hepatitis C Virus (HCV) protease inhibitor with ritonavir in healthy volunteers.

Detailed description

This is an open-label, randomized, 2 cross-over period fasting and non-fasting study.

Conditions

• HCV Infection

Interventions

Type	Name	Description
DRUG	ABT-450	capsules, QD, 1 dose in each cross-over period
DRUG	ritonavir	capsule, QD, 1 dose in each cross-over period

Timeline

• Start date: 2009-05-01
• Primary completion: 2009-07-01
• First posted: 2009-05-28
• Last updated: 2010-10-13

Locations

1 site across 1 country: United States